Exagen (XGN) Competitors

$3.43 -0.21 (-5.77%)

As of 12:27 PM Eastern

XGN vs. AUNA, VMD, SBC, AIRS, and LFMD

Should you buy Exagen stock or one of its competitors? MarketBeat compares Exagen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Exagen include Auna (AUNA), Viemed Healthcare (VMD), SBC Medical Group (SBC), AirSculpt Technologies (AIRS), and LifeMD (LFMD). These companies are all part of the "healthcare" industry.

How does Exagen compare to Auna?

Auna (NYSE:AUNA) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

Auna has a net margin of 2.13% compared to Exagen's net margin of -29.49%. Auna's return on equity of 19.23% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Auna	2.13%	19.23%	4.70%
Exagen	-29.49%	-94.37%	-28.96%

Auna currently has a consensus price target of $7.30, indicating a potential upside of 48.68%. Exagen has a consensus price target of $9.25, indicating a potential upside of 169.68%. Given Exagen's stronger consensus rating and higher probable upside, analysts clearly believe Exagen is more favorable than Auna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Auna	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Exagen had 8 more articles in the media than Auna. MarketBeat recorded 9 mentions for Exagen and 1 mentions for Auna. Exagen's average media sentiment score of 0.49 beat Auna's score of -0.45 indicating that Exagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Auna	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exagen	0 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Auna has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, Exagen has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

75.3% of Exagen shares are owned by institutional investors. 12.6% of Exagen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Auna has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Auna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Auna	$1.23B	0.30	$27.39M	$0.36	13.64
Exagen	$68.38M	1.21	-$19.95M	-$0.89	N/A

Summary

Exagen beats Auna on 9 of the 17 factors compared between the two stocks.

How does Exagen compare to Viemed Healthcare?

Exagen (NASDAQ:XGN) and Viemed Healthcare (NASDAQ:VMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

75.3% of Exagen shares are held by institutional investors. Comparatively, 74.2% of Viemed Healthcare shares are held by institutional investors. 12.6% of Exagen shares are held by company insiders. Comparatively, 20.0% of Viemed Healthcare shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Exagen had 8 more articles in the media than Viemed Healthcare. MarketBeat recorded 9 mentions for Exagen and 1 mentions for Viemed Healthcare. Viemed Healthcare's average media sentiment score of 0.94 beat Exagen's score of 0.49 indicating that Viemed Healthcare is being referred to more favorably in the news media.

Company	Overall Sentiment
Exagen	Neutral
Viemed Healthcare	Positive

Viemed Healthcare has a net margin of 5.20% compared to Exagen's net margin of -29.49%. Viemed Healthcare's return on equity of 10.52% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
Viemed Healthcare	5.20%	10.52%	7.60%

Viemed Healthcare has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$68.38M	1.21	-$19.95M	-$0.89	N/A
Viemed Healthcare	$286.57M	1.26	$14.93M	$0.37	25.55

Exagen has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market. Comparatively, Viemed Healthcare has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Exagen presently has a consensus target price of $9.25, suggesting a potential upside of 169.68%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Viemed Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Viemed Healthcare	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Viemed Healthcare beats Exagen on 10 of the 16 factors compared between the two stocks.

How does Exagen compare to SBC Medical Group?

SBC Medical Group (NASDAQ:SBC) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

60.8% of SBC Medical Group shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 89.5% of SBC Medical Group shares are owned by insiders. Comparatively, 12.6% of Exagen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

SBC Medical Group has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, Exagen has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

SBC Medical Group has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SBC Medical Group	$173.61M	1.73	$50.99M	$0.39	7.51
Exagen	$68.38M	1.21	-$19.95M	-$0.89	N/A

In the previous week, SBC Medical Group had 6 more articles in the media than Exagen. MarketBeat recorded 15 mentions for SBC Medical Group and 9 mentions for Exagen. Exagen's average media sentiment score of 0.49 beat SBC Medical Group's score of -0.14 indicating that Exagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SBC Medical Group	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exagen	0 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SBC Medical Group has a net margin of 24.09% compared to Exagen's net margin of -29.49%. SBC Medical Group's return on equity of 15.90% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SBC Medical Group	24.09%	15.90%	11.61%
Exagen	-29.49%	-94.37%	-28.96%

SBC Medical Group currently has a consensus target price of $8.50, indicating a potential upside of 190.10%. Exagen has a consensus target price of $9.25, indicating a potential upside of 169.68%. Given SBC Medical Group's higher probable upside, equities analysts clearly believe SBC Medical Group is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SBC Medical Group	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

SBC Medical Group beats Exagen on 11 of the 16 factors compared between the two stocks.

How does Exagen compare to AirSculpt Technologies?

AirSculpt Technologies (NASDAQ:AIRS) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

AirSculpt Technologies currently has a consensus target price of $4.50, suggesting a potential downside of 4.96%. Exagen has a consensus target price of $9.25, suggesting a potential upside of 169.68%. Given Exagen's stronger consensus rating and higher probable upside, analysts clearly believe Exagen is more favorable than AirSculpt Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AirSculpt Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

91.5% of AirSculpt Technologies shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 44.6% of AirSculpt Technologies shares are held by insiders. Comparatively, 12.6% of Exagen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

AirSculpt Technologies has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market. Comparatively, Exagen has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

AirSculpt Technologies has higher revenue and earnings than Exagen. AirSculpt Technologies is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AirSculpt Technologies	$151.82M	2.20	-$11.67M	-$0.17	N/A
Exagen	$68.38M	1.21	-$19.95M	-$0.89	N/A

AirSculpt Technologies has a net margin of -7.39% compared to Exagen's net margin of -29.49%. AirSculpt Technologies' return on equity of -4.98% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AirSculpt Technologies	-7.39%	-4.98%	-2.36%
Exagen	-29.49%	-94.37%	-28.96%

In the previous week, Exagen had 7 more articles in the media than AirSculpt Technologies. MarketBeat recorded 9 mentions for Exagen and 2 mentions for AirSculpt Technologies. AirSculpt Technologies' average media sentiment score of 0.94 beat Exagen's score of 0.49 indicating that AirSculpt Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AirSculpt Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exagen	0 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

AirSculpt Technologies beats Exagen on 11 of the 16 factors compared between the two stocks.

How does Exagen compare to LifeMD?

Exagen (NASDAQ:XGN) and LifeMD (NASDAQ:LFMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Exagen has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market. Comparatively, LifeMD has a beta of 2.03, meaning that its share price is 103% more volatile than the broader market.

Exagen currently has a consensus price target of $9.25, indicating a potential upside of 169.68%. LifeMD has a consensus price target of $9.14, indicating a potential upside of 113.87%. Given Exagen's stronger consensus rating and higher probable upside, research analysts clearly believe Exagen is more favorable than LifeMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
LifeMD	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

LifeMD has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$68.38M	1.21	-$19.95M	-$0.89	N/A
LifeMD	$193.33M	1.07	$14.35M	$0.05	85.50

75.3% of Exagen shares are held by institutional investors. Comparatively, 35.5% of LifeMD shares are held by institutional investors. 12.6% of Exagen shares are held by company insiders. Comparatively, 18.4% of LifeMD shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Exagen had 7 more articles in the media than LifeMD. MarketBeat recorded 9 mentions for Exagen and 2 mentions for LifeMD. LifeMD's average media sentiment score of 0.93 beat Exagen's score of 0.49 indicating that LifeMD is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	0 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LifeMD	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LifeMD has a net margin of 2.37% compared to Exagen's net margin of -29.49%. Exagen's return on equity of -94.37% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
LifeMD	2.37%	-150.88%	-22.59%

Summary

LifeMD beats Exagen on 9 of the 16 factors compared between the two stocks.

Get Exagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XGN vs. The Competition

Export

Metric	Exagen	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$82.89M	$8.19B	$6.23B	$12.22B
Dividend Yield	N/A	2.54%	2.81%	5.30%
P/E Ratio	-3.86	15.93	20.55	25.17
Price / Sales	1.21	8.11	544.49	71.25
Price / Cash	N/A	16.74	27.48	37.27
Price / Book	4.45	3.57	9.71	6.65
Net Income	-$19.95M	$224.05M	$3.56B	$335.32M
7 Day Performance	-13.82%	-3.04%	-1.66%	-1.61%
1 Month Performance	11.36%	-3.65%	-2.35%	-0.96%
1 Year Performance	-42.93%	0.43%	31.59%	28.59%

Exagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XGN Exagen	4.1279 of 5 stars	$3.43 -5.8%	$9.25 +169.7%	-39.4%	$82.89M	$68.38M	N/A	220	Earnings Report
AUNA Auna	4.1871 of 5 stars	$4.92 -2.6%	$7.30 +48.5%	-31.1%	$373.77M	$1.23B	13.66	15,254	Upcoming Earnings Analyst Downgrade High Trading Volume
VMD Viemed Healthcare	2.0689 of 5 stars	$9.36 +3.7%	N/A	+38.3%	$346.18M	$270.28M	25.30	1,382
SBC SBC Medical Group	4.3943 of 5 stars	$3.31 +4.7%	$8.50 +156.8%	-12.6%	$324.14M	$173.61M	6.76	N/A	Earnings Report Analyst Revision
AIRS AirSculpt Technologies	1.7678 of 5 stars	$4.16 -4.4%	$6.00 +44.2%	+34.5%	$306.87M	$151.82M	N/A	240

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XGN) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exagen (XGN) Competitors

XGN vs. AUNA, VMD, SBC, AIRS, and LFMD

How does Exagen compare to Auna?

Summary

How does Exagen compare to Viemed Healthcare?

Summary

How does Exagen compare to SBC Medical Group?

Summary

How does Exagen compare to AirSculpt Technologies?

Summary

How does Exagen compare to LifeMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exagen (XGN) Competitors

XGN vs. AUNA, VMD, SBC, AIRS, and LFMD

How does Exagen compare to Auna?

Is AUNA or XGN more profitable?

Do analysts recommend AUNA or XGN?

Does the media refer more to AUNA or XGN?

Which has more risk & volatility, AUNA or XGN?

Do insiders and institutionals have more ownership in AUNA or XGN?

Which has preferable valuation and earnings, AUNA or XGN?

Summary

How does Exagen compare to Viemed Healthcare?

Do insiders & institutionals hold more shares of XGN or VMD?

Does the media prefer XGN or VMD?

Is XGN or VMD more profitable?

Which has stronger earnings and valuation, XGN or VMD?

Which has more volatility and risk, XGN or VMD?

Do analysts recommend XGN or VMD?

Summary

How does Exagen compare to SBC Medical Group?

Do institutionals and insiders believe in SBC or XGN?

Which has more risk and volatility, SBC or XGN?

Which has higher valuation and earnings, SBC or XGN?

Does the media refer more to SBC or XGN?

Is SBC or XGN more profitable?

Do analysts rate SBC or XGN?

Summary

How does Exagen compare to AirSculpt Technologies?

Do analysts rate AIRS or XGN?

Do institutionals and insiders hold more shares of AIRS or XGN?

Which has more risk and volatility, AIRS or XGN?

Which has preferable earnings & valuation, AIRS or XGN?

Is AIRS or XGN more profitable?

Does the media favor AIRS or XGN?

Summary

How does Exagen compare to LifeMD?

Which has more volatility and risk, XGN or LFMD?

Do analysts rate XGN or LFMD?

Which has stronger earnings and valuation, XGN or LFMD?

Do institutionals & insiders believe in XGN or LFMD?

Does the media refer more to XGN or LFMD?

Is XGN or LFMD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools